Loading clinical trials...
Loading clinical trials...
A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
Conditions
Interventions
Dapagliflozin 10mg
Locations
7
Canada
Nephrology Dept., Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada
Division of Nephrology University Health Network, University of Toronto
Toronto, Ontario, Canada
Nephrology Unit, University Kebangsaan Malaysia
Kuala Lumpur, Malaysia
University Malaya Medical Centre, Ward 8TE
Kuala Lumpur, Malaysia
Dept Internal Medicine, division of Nephrology Hospital Group Twente
Almelo, Netherlands
Dept.of Nephrology, VU University Medical Center
Amsterdam, Netherlands
Start Date
November 12, 2017
Primary Completion Date
November 1, 2019
Completion Date
December 1, 2019
Last Updated
June 17, 2024
NCT00977977
NCT06337838
NCT05318196
NCT05728216
NCT04592640
NCT06578078
Lead Sponsor
Hiddo Lambers Heerspink
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions